Industry Supported Symposium 2: Genomic Strategies for Screening, Prevention and Clinical Intervention for Ovarian Cancer

Description: Supported by Myriad, CME/CNE Provided by Letters & Sciences and the University of North Texas Science Center This CME/CNE symposium highlights practice-changing developments that underscore the importance of providing access to BRCA1/2 screening as a critical clinical tool in altering hereditary ovarian and breast cancer risk. Equally as important as access to screening and expanded prevention strategies are recent advances in genomics and molecularly targeted treatment that continue to evolve and improve. This distinguished faculty of leading clinicians and researchers will focus on what practitioners need to know and how they can readily incorporate these new data and strategies into clinical practice, including a review of the role of BRCA in oncogenesis, updated screening guidelines, genomic technologies, and clinical interventions for risk reduction and treatment of hereditary ovarian and breast cancers. Register at directrsvp.com/OCStrategies or by calling 800 238-9620, PIN 6879.